Message #75 From:
NewsBot Date: November 22, 2006 07:00:00 AM
NYMX News Newly Published Editorial in Expert Opinion on Investigational Drugs Says Statins May Be Good for Alzheimer's Disease
HASBROUCK HEIGHTS, N.J.--(BUSINESS WIRE)--A newly published editorial in Expert Opinion on Investigational
Drugs has concluded that statins, the widely used cholesterol drugs, “probably
strike at the heart of the sporadic Alzheimer’s
disease-inducing mechanism” (Expert Opin.
Investig. Drugs (Dec. 2006) 15(12):1479-1485). The editorial, “Can
statins put the brakes on Alzheimer’s disease?”,
reviews current research into the potential benefits that statins may
offer for the prevention or treatment of Alzheimer’s
disease and concludes that statins can affect Alzheimer’s
disease (AD) in at least two ways: by reducing cerebrovascular damage
and by inhibiting some of the biochemical pathways believed to be
implicated in the disease process.
This is more good news for Nymox Pharmaceutical Corporation
(NASDAQ:NYMX), the company which holds U.S. and global patent rights for
the use of statin drugs for the prevention and treatment of AD,
including for patients at risk for AD because of vascular-related risk
factors or disease.
This may become welcome good news for AD patients and their families.
Statins are well-known, widely available cholesterol-lowering drugs with
a well-established track record of safety and may offer a relatively
straightforward regulatory path to a new treatment for Alzheimer’s
disease. Statins are the biggest-selling prescription pills in
pharmaceutical history with estimated 2004 global sales of $26 billion.
Further trials are needed to advance these findings according to the
editorial.
November is National Alzheimer's Disease Awareness Month and also the
100th anniversary of the first report of Dr. Alois Alzheimer
characterizing the hallmarks of the disease. Alzheimer's disease is the
leading cause of dementia in the elderly, afflicting an estimated 4.5
million people in the U.S. and 15 million worldwide.
This press release contains certain “forward-looking
statements” as defined in the United States
Private Securities Litigation Reform Act of 1995 that involve a number
of risks and uncertainties. There can be no assurance that such
statements will prove to be accurate and the actual results and future
events could differ materially from management's current expectations.
The conduct of clinical trials and the development of drug products
involve substantial risks and uncertainties and actual results may
differ materially from expectations. Promising early results do not
ensure that later stage or larger scale clinical trials will be
successful or will proceed as expected. Such factors are detailed from
time to time in Nymox's filings with the United States Securities and
Exchange Commission and other regulatory authorities.
